NCT01640691View on ClinicalTrials.gov

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 10, 2012

Primary Completion Date

January 2, 2013

Study Completion Date

June 30, 2013

Conditions
Pandemic Influenza
Interventions
BIOLOGICAL

Pandemic Influenza Vaccine (H5N1)

"Inactivated whole-virion vaccine~1. Administration route: Intramuscular Injection~2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately~3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"

Trial Locations (1)

Unknown

National Cheng Kung University Hospital, Tainan City

Sponsors
All Listed Sponsors
lead

Adimmune Corporation

INDUSTRY